The Centre has cleared two more vaccines and one anti-viral drug to boost the fight against the COVID-19 pandemic. Health Minister Dr Mansukh Mandaviya announced that the Central Drugs Standard Control Organisation under the Ministry of Health and Family Welfare has given emergency use authorization approval to COVID19 vaccines Covovax and Corbevax and Anti-viral drug Molnupiravir.
Six COVID-19 vaccines — Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Zydus Cadila’s ZyCoV-D, Russia’s Sputnik V and the US-made Moderna and Johnson and Johnson — had already received EUA from the Indian drug regulator earlier.
CORBEVAX vaccine is India’s 1st indigenously developed RBD protein sub-unit vaccine against #COVID19, Made by Hyderabad-based firm Biological-E.
It’s a hat-trick! It’s now 3rd vaccine developed in India! (2/5)
— Dr Mansukh Mandaviya (@mansukhmandviya) December 28, 2021
“Corbevax vaccine is India’s 1st indigenously developed RBD protein sub-unit vaccine against #COVID19, Made by Hyderabad-based firm Biological-E. It’s a hat-trick! It’s now 3rd vaccine developed in India,” Mandaviya said in another tweet.
The Nanoparticle Vaccine, Covovax, will be manufactured by Pune-based firm Serum Institute of India, he said.
“Molnupiravir, an antiviral drug, will now be manufactured in the country by 13 companies for restricted use under emergency situation for treatment of adult patients with COVID-19 and who have high risk of progression of the disease,” Mandaviya said.
Molnupiravir, an antiviral drug, will now be manufactured in the country by 13 companies for restricted use under emergency situation for treatment of adult patients with COVID-19 and who have high risk of progression of the disease. (4/5)
— Dr Mansukh Mandaviya (@mansukhmandviya) December 28, 2021